Related Research Articles
The Medical University of South Carolina (MUSC) is a public medical school in Charleston, South Carolina. It opened in 1824 as a small private college aimed at training physicians and has since established hospitals and medical facilities across the state. It is one of the oldest continually operating schools of medicine in the United States and the oldest in the Deep South.
Emil "Tom" Frei III was an American physician and oncologist. He was the former director and former physician-in-chief of the Dana–Farber Cancer Institute in Boston, Massachusetts. He was also the Richard and Susan Smith Distinguished Professor of Medicine at Harvard Medical School.
Graham Andrew Colditz MD, DrPH is an Australian chronic disease epidemiologist. He is the inaugural Niess-Gain Professor at Washington University School of Medicine, where he is associate director for Prevention and Control at the Alvin J. Siteman Cancer Center. He directs the Master of Population Health Science at Washington University School of Medicine. During medical training he was excited by the potential for prevention of chronic diseases. With encouragement from mentors he pursued training in the US as it was routine for academics in Australia to obtain overseas training at that time. He is internationally recognized for leadership in cancer prevention, and is often interviewed by media for input on this topic. With members of Cancer Prevention and Control at Siteman, he blogs on issues relating to cancer prevention and screening. According to Google Scholar statistics, Colditz has a h-index of more than 300.
Joseph F. Fraumeni Jr. is an American physician and cancer researcher. Born in Boston, he received an A.B. from Harvard College, an M.D. from Duke University, and an M.Sc. in epidemiology from the Harvard School of Public Health. He completed his medical residency at Johns Hopkins Hospital and Memorial Sloan-Kettering Cancer Center. He then joined the National Cancer Institute at the National Institutes of Health in 1962 as a commissioned officer of the U.S. Public Health Service, becoming the founding Director of the Division of Cancer Epidemiology and Genetics in 1995. He stepped down from this position in 2012 to become a senior investigator and advisor to the National Cancer Institute.
Aviv Regev is a computational biologist and systems biologist and Executive Vice President and Head of Genentech Research and Early Development in Genentech/Roche. She is a core member at the Broad Institute of MIT and Harvard and professor at the Department of Biology of the Massachusetts Institute of Technology. Regev is a pioneer of single cell genomics and of computational and systems biology of gene regulatory circuits. She founded and leads the Human Cell Atlas project, together with Sarah Teichmann.
Otis Webb Brawley is an American physician and the Bloomberg Distinguished Professor of Oncology and Epidemiology at Johns Hopkins University. He served as Chief Medical and Scientific Officer and Executive Vice President of the American Cancer Society from July 2007 to November 2018. He is board certified in internal medicine and medical oncology and is a Master of the American College of Physicians, Fellow of the American Society of Clinical Oncology, and a Fellow of the American College of Epidemiology. He is a member of the Institute of Medicine now known as the National Academy of Medicine.
Waun Ki Hong was Professor of Medicine at The University of Texas MD Anderson Cancer Center, where he served as chairman of the Department of Thoracic/Head & Neck Medical Oncology from 1993 to 2005 and as head of the Division of Cancer Medicine from 2001 to 2014. He was also an American Cancer Society Professor and the Samsung Distinguished University Chair in Cancer Medicine emeritus.
Richard David Kolodner is an American scientist with Ludwig Cancer Research who has made research contributions to the genetic basis for inherited susceptibility to common cancers. He is a Distinguished Professor of Cellular and Molecular Medicine at the UC San Diego School of Medicine. Kolodner is a member of the National Academy of Sciences and National Academy of Medicine, and he is a fellow of the American Academy of Arts and Sciences.
William G. Kaelin Jr. is an American Nobel laureate physician-scientist. He is a professor of medicine at Harvard University and the Dana–Farber Cancer Institute. His laboratory studies tumor suppressor proteins. In 2016, Kaelin received the Albert Lasker Award for Basic Medical Research and the AACR Princess Takamatsu Award. He also won the Nobel Prize in Physiology or Medicine in 2019 along with Peter J. Ratcliffe and Gregg L. Semenza.
Michael A. Caligiuri, M.D. is a physician scientist focused on oncology and immunology. He is currently the president of the City of Hope National Medical Center and the Deana and Steve Campbell Physician-in-Chief Distinguished Chair. He was elected president of the American Association for Cancer Research, the world's largest cancer research organization, for 2017–2018. He was previously the CEO of the James Cancer Hospital (2008-2017), Director of the Comprehensive Cancer Center (2003-2017), and Director of the Division of Hematology-Oncology (2000-2008) at the Ohio State University. He was elected to the United States National Academy of Medicine in 2018.
David M. Livingston was the Deputy Director of the Dana-Farber/Harvard Cancer Center, Emil Frei Professor of Genetics and Medicine at Harvard Medical School, Chairman of the Executive Committee for Research at Dana–Farber Cancer Institute. Dr. Livingston joined the Harvard faculty in 1973. His research focused on breast and ovarian cancer.
Webster K. "Web" Cavenee is the Director of Strategic Alliances in Central Nervous System Cancers at the Ludwig Institute for Cancer Research and Distinguished Professor at the University of California, San Diego. He was the Director of the Ludwig Institute for Cancer Research until 2015 when it was taken over by Richard Kolodner. His laboratory studies gene mutations in cancer, most notably in EGFR and glioblastoma multiforme.
Scott M. Lippman is the director of Moores Cancer Center at the University of California, San Diego and Professor of Medicine at UC San Diego School of Medicine.
Michael B. Sporn is a professor emeritus of pharmacology, toxicology and medicine at Dartmouth Medical School. His research focuses on the prevention of cancer.
Daniel D. Von Hoff is the physician in chief and director of translational research at Translational Genomics Research Institute (TGen), and current Virginia G. Piper Distinguished Chair for Innovative Cancer Research at HonorHealth Clinical Research Institute. He is also a professor of medicine at the Mayo Clinic and medical director of research as well as chief scientific officer at US Oncology. He is most notable for his work in targeted therapies for the treatment of cancer. He led the development of gemcitabine, and has several drugs in development.
Curtis. C. Harris is the head of the Molecular Genetics and Carcinogenesis Section and chief of the Laboratory of Human Carcinogenesis at the Center for Cancer Research of the National Cancer Institute, NIH.
Judy Ellen Garber is the director of the Center for Cancer Genetics and Prevention at the Dana–Farber Cancer Institute and a professor of medicine at Harvard Medical School. Garber previously served as president of the American Association for Cancer Research.
Kornelia Polyak is a professor of medicine at Harvard Medical School and an internationally recognized breast cancer expert.
Chanita Ann Hughes-Halbert is an American psychologist and medical researcher. She is professor of psychiatry and behavioral sciences at the Medical University of South Carolina and the AT&T Distinguished Endowed Chair for Cancer Equity at the Hollings Cancer Center. She is the first woman and first African American from South Carolina elected to the National Academy of Medicine.
Roy S. Herbst is an American oncologist who is the Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, and Associate Director for Translational Research at Yale Cancer Center and Yale School of Medicine in New Haven, Connecticut.
References
- 1 2 "MUSC Hollings Cancer Center director receives AACR Distinguished Service Award".
- 1 2 "The Mark Foundation for Cancer Research appoints Raymond N. DuBois as executive chairman". The Post and Courier .
- 1 2 3 4 5 6 "Raymond N. DuBois - MUSC Health Charleston SC".
- 1 2 3 4 5 6 7 "Raymond N. DuBois Receives Landon Prize". Journal of Investigative Medicine . ProQuest 2032729005 . Retrieved 2022-06-29.
- ↑ "DuBois picked to lead". The Tennessean .
- 1 2 3 4 5 6 "DuBois named director of MUSC Hollings Cancer Center". Charleston Business Journal.
- ↑ "LOCAL BUSINESS. Director to leave Vanderbilt-Ingram". The Tennessean .
- 1 2 "AACR Congratulates Dr. Raymond N. DuBois on His Appointment as Executive Director of Arizona State University's Biodesign Institute". ProQuest 1095454901.
- ↑ "Dr. Raymond DuBois appointed director of MUSC Hollings Cancer Center". Beckers Hospital Review.
- ↑ "Inflammation and Inflammatory Mediators as Potential Targets for Cancer Prevention or Interception". Cancer Prevention Fellowship Program.